Last reviewed · How we verify

NCT06011681

The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over

Status unknown Last updated 22 January 2024
What this trial tests

trial in Depression in 960 participants. Status unknown.

Timeline
8 September 2023
Primary endpoint
30 November 2024
31 December 2024

Quick facts

Lead sponsorMiro Health
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment960
Start date8 September 2023
Primary completion30 November 2024
Estimated completion31 December 2024
Sites2 locations across United States

Conditions studied

Sponsor

Miro Health

Who can join

60 and older, any sex, with Depression or Mild Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Mild cognitive impairment (MCI) leading to Alzheimer's disease and related disorders (ADRD) represents a significant health and economic burden of the rapidly expanding senior population. The accurate detection and diagnosis of MCI and its common comorbidity, late-life depression (LLD), is essential for prolonging patient quality of life and developing advancements in research and treatment options. The purpose of the proposed program is to refine Miro Health's A.I. to accurately detect, differentiate and diagnose MCI and LLD.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Depression

Currently open trials in the same condition.

Other Miro Health trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06011681.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing